| Literature DB >> 33765432 |
Omar H Butt1, Justin M Long2, Rachel L Henson3, Elizabeth Herries3, Courtney L Sutphen3, Anne M Fagan2, Carlos Cruchaga4, Jack H Ladenson5, David M Holtzman2, John C Morris6, Beau M Ances7, Suzanne E Schindler8.
Abstract
Cerebrospinal fluid (CSF) synaptosomal-associated protein 25 (SNAP-25) and neurogranin (Ng) are recently described biomarkers for pre- and postsynaptic integrity known to be elevated in symptomatic Alzheimer disease (AD). Their relationship with Apolipoprotein E (APOE) ε4 carrier status, the major genetic risk factor for AD, remains unclear. In this study, CSF SNAP-25 and Ng were compared in cognitively normal APOE ε4 carriers and noncarriers (n = 274, mean age 65 ± 9.0 years, 39% APOE ε4 carriers, 58% female). CSF SNAP-25, not CSF Ng, was specifically elevated in APOE ε4 carriers versus noncarriers (5.95 ± 1.72 pg/mL, 4.44 ± 1.40 pg/mL, p < 0.0001), even after adjusting for age, sex, years of education, and amyloid status (p < 0.0001). CSF total tau (t-tau), phosphorylated-tau-181 (ptau181), and neurofilament light chain (NfL) also did not vary by APOE ε4 status. Our findings suggest APOE ε4 carriers have amyloid-related and amyloid-independent presynaptic disruption as reflected by elevated CSF SNAP-25 levels. In contrast, postsynaptic disruption as reflected by elevations in CSF neurogranin is related to amyloid status.Entities:
Keywords: APOE; Biomarker; CSF; Neurogranin; SNAP-25; Synapse
Mesh:
Substances:
Year: 2021 PMID: 33765432 PMCID: PMC8793109 DOI: 10.1016/j.neurobiolaging.2021.02.008
Source DB: PubMed Journal: Neurobiol Aging ISSN: 0197-4580 Impact factor: 5.133